News

Article

Ofranergene Obadenovec Plus Paclitaxel Misses the Mark in Platinum-Resistant Ovarian Cancer

Author(s):

The addition of ofranergene obadenovec to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer.

Rebecca C. Arend, MD, MSPH

Rebecca C. Arend, MD, MSPH

The addition of ofranergene obadenovec (ofra-vec; VB-111) to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, according to data from the phase 3 OVAL trial (GOG 3018; NCT03398655) presented at the 2023 ASCO Annual Meeting.1

The median progression-free survival (PFS) with ofra-vec plus paclitaxel (n = 204) was 5.29 months vs 5.36 months with paclitaxel alone (n = 205; HR, 1.0320; 95% CI, 0.8252-1.2908; P = .7823). Additionally, the median overall survival (OS) was 13.37 months in the investigative arm and 13.14 months in the control arm (HR, 0.9738; 95% CI, 0.7475-1.2687; P = .8440).

“The addition of ofra-vec to paclitaxel did not improve PFS or OS, which was unexpected in view of the phase 1/2 experience, and the interim analysis of CA-125 response,” lead study author Rebecca C. Arend, MD, MSPH, of the University of Alabama at Birmingham School of Medicine, said in a presentation of the data. “Future studies in the platinum-resistant setting should include agents that exploit the potential synergy of targeting angiogenesis and vascular integrity in cancer.”

Ofra-vec is a nonreplicating adenoviral vector with a murine PPE-1-3X promoter and pro-apoptotic TNFR1 chimeric transgene that is hypothesized to have a dual mechanism of action of vascular disruption and immune activation.

Study participants were randomly assigned 1:1 to receive placebo every 8 weeks plus paclitaxel at 80 mg/m2 once weekly (n = 200) or ofra-vec at 1 x 1013 viral particles every 8 weeks plus paclitaxel at the same dose once weekly (n = 200). Treatment continued until disease progression.

The co-primary end points of OVAL were PFS and OS by blinded independent central review. PFS was first tested at 0.015 significance level and OS was tested at a significance level of 0.05 if the PFS reached significance, and at a level of 0.035 if otherwise. The overall significance level for the trial was 0.05, and a 90% power was leveraged to detect hazard ratio for PFS and OS.

Secondary end points comprised objective response rate (ORR) by CA-125 and RECIST v1.1 criteria combined and individually, as well as OS100. Translational scientific objectives comprised histopathology, expression, and biomarkers.

A total of 537 patients underwent screening and 409 patients were randomized; 204 were assigned to the investigative arm and 205 were assigned to the control arm. Ultimately, 203 patients were treated with ofra-vec plus paclitaxel and 202 were treated with placebo plus paclitaxel.

In the investigative arm, 185 patients discontinued treatment; the most common reason for this was progressive disease (PD) by RECIST criteria (n = 136), followed by PD not by RECIST criteria (n = 20), safety (n = 8), patient request (n = 8), investigator decision (n = 7), WOC (n = 3), and death (n = 3). Eighteen patients were still receiving treatment at the time of data cutoff.

Across the arms, the median age was 61.6 years; 78.8% of patients were White and 92% were not Hispanic or Latino. In the investigative arm, 77.5% of patients had epithelial ovarian cancer, 12.3% had primary peritoneal disease, and 10.3% had fallopian tube disease; in the control arm, these rates were 72.7%, 13.7%, and 13.7%, respectively. Of those who received ofra-vec plus paclitaxel, 61.8%, 38.2%, and 0% had an ECOG performance status of 0, 1, or 2, respectively; these rates were 62%, 36.6%, and 1.5%, respectively, for those who received paclitaxel alone.

More than half the patients across the ofra-vec/paclitaxel (58.8%) and placebo/paclitaxel (67.8%) arms had stage III disease. Most patients had grade 3 disease (92.2%; 90.2%) and serous adenocarcinoma (89.2%; 94.6%). Additionally, 20.1% of those in the investigative arm and 17.6% of those in the control arm had BRCA-positive disease.

The mean number of prior therapies received in both arms was 3. In the investigative arm, 7.4% of patients had 1 prior line, 30.9% had 2 lines, 32.4% had 3 lines, 17.6% had 4 lines, 10.8% had 5 lines, and 1.0% had 6 or more lines; in the control arm, these rates were 8.8%, 29.3%, 20.5%, 11.7%, and 0.5%, respectively. More than half of patients in the investigative and control arms were previously exposed to PARP inhibitors (62.7%; 66.3%) and antiangiogenics (70.1%; 69.3%). Additionally, 79.9% of patients in the ofra-vec arm were evaluable for CA-125 response, as were 75.1% of those in the placebo arm.

Regarding safety, adverse effects (AEs) were experienced by 98.5% of those in the investigative arm and 99.5% of those in the placebo arm; 90.1% and 75.9% of patients, respectively, had AEs related to ofra-vec or placebo, and 93.1% of patients in both arms had AEs related to paclitaxel. Grade 3 or higher toxicities were observed in 60.6% and 53.7% of patients, respectively; these effects were related to ofra-vec or placebo in 25.6% and 14.8% of patients, respectively.

Additionally, 31% of those in the ofra-vec arm experienced serious AEs vs 26.6% of those in the placebo arm; these effects were related to ofra-vec or placebo in 5.9% and 3.0% of patients, respectively, and related to paclitaxel in 7.9% and 5.9% of patients, respectively.

In the investigative arm, AEs resulted in dose interruption or discontinuation of ofra-vec for 16.7% and 3.9% of patients, respectively. In this arm, dosing of paclitaxel was interrupted for 62.6% of patients, reduced for 27.1% of patients, and discontinued for 6.9% of patients—all due to AEs. Three patients experienced serious AEs that resulted in ofra-cel discontinuation. Three patients had fatal AEs but none were determined to be related to the study drug.

In the placebo arm, 6.9% and 14.8% of patients, respectively, needed dose interruptions or discontinuation due to toxicity. In this group, dosing of paclitaxel was interrupted, reduced, or discontinued in 47.3%, 25.1%, and 9.9% of patients, respectively. Serious toxicities resulting in discontinuation of placebo or paclitaxel occurred in 3.4% and 3.0% of patients, respectively. Four patients experienced a fatal AE, but none were determined to be related to placebo.

“The AE pattern was as expected for an adenovirus-based viral therapy and reflected the product’s established safety profile,” Arend concluded.

Reference

Arend RC, Monk BJ, Shapira-Frommer R, et al. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL study/GOG 3018). J Clin Oncol. 2023;41(suppl 16):5505. doi:10.1200/JCO.2023.41.16_suppl.5505

Related Videos
Laura J. Chambers, DO
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Laura J. Chambers, DO
Angeles A. Secord, MD, MHSc
Amitkumar Mehta, MD
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Kimberly Cannavale, MPH
Kimberly Cannavale, MPH